TITLE

Increased expression of interleukin 17 in inflammatory bowel disease

AUTHOR(S)
Fujino, S.; Andoh, A.; Bamba, S.; Ogawa, A.; Hata, K.; Araki, Y.; Bamba, T.; Fujiyama, Y.
PUB. DATE
January 2003
SOURCE
Gut;Jan2003, Vol. 52 Issue 1, p65
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background and aim: Interleukin (IL) 17 is a cytokine which exerts strong proinflammatory activities. In this study we evaluated changes in IL-17 expression in the inflamed mucosa and in the serum of patients with inflammatory bowel disease (IBD). Methods: Tissue samples were obtained endoscopically or surgically from patients with ulcerative colitis (UC) (n=20), Crohn's disease (CD) (n=20), infectious colitis (n=5), ischaemic colitis (n=8), and normal colorectal tissues (n=15). IL-17 expression was evaluated by a standard immunohistochemical procedure. Serum IL-17 levels were determined by ELISA. IL-17 mRNA expression was analysed by reverse transcriptase-polymerase chain reaction. Results: IL-17 expression was not detected in samples from normal colonic mucosa, infectious colitis, or ischaemic colitis. In the inflamed mucosa of active UC and CD patients, IL-17 expression was clearly detectable in CD3[sup +] T cells or CD68[sup +] monocytes/macrophages. The average number of IL-17[sup +] cells was significantly increased in active UC and CD patients compared with inactive patients. IL-17 mRNA expression was not detected in normal mucosa but was detectable in the mucosa from active UC and CD patients. IL-17 was not detected in the sera from normal individuals, infectious colitis, or ischaemic colitis patients but IL-17 levels were significantly elevated in IBD patients. Conclusions: IL-17 expression in the mucosa and serum was increased in IBD patients. It is likely that IL-17 expression in IBD may be associated with altered immune and inflammatory responses in the intestinal mucosa.
ACCESSION #
9758408

 

Related Articles

  • Editorial: The Impact of Microbiota and Cytokines on Inflammatory Bowel Disease. Kanauchi, Osamu; Mitsuyama, Keiichi // Current Pharmaceutical Design;6/21/2009, Vol. 15 Issue 18, p2049 

    The article discusses a special issue on the role of microbiota and cytokines in inflammatory bowel disease (IBD) including the therapeutic impact of manipulating microbiota in IBD, the effects of curcumin on IBD patients, and the role of interleukin-6 in IBD.

  • Dextran sulphate sodium-induced colitis is ameliorated in interleukin 4 deficient mice. Stevceva, L; Pavli, P; Husband, A; Ramsay, A; Doe, W F // Genes & Immunity;Oct2001, Vol. 2 Issue 6, p309 

    The importance of IL-4 and its effects in inflammatory bowel disease (IBD) was studied using the dextran sulphate sodium-induced model of experimental colitis. The model resembles ulcerative colitis in humans. IL-4 deficient mice and IL-4+/+ littermates were used to induce colitis. Activity of...

  • Is interleukin-6 important in inflammatory bowel disease? Koss, K; Satsangi, J; Welsh, K I; Jewell, D P // Genes & Immunity;Feb2000, Vol. 1 Issue 3, p207 

    The IL-6 gene maps to an area of chromosome 7 known to be significant for susceptibility to inflammatory bowel disease. The functional effects of interleukin-6 (IL-6) polymorphisms in the 4th intron and in the 3' flanking region of IL-6 gene were studied in 192 inflammatory bowel disease...

  • Novel Pharmacological Approaches for Inflammatory Bowel Disease: Targeting Key Intracellular Pathways and the IL-23/IL-17 Axis. Fitzpatrick, Leo R. // International Journal of Inflammation;2012, p1 

    This review identifies possible pharmacological targets for inflammatory bowel disease (IBD) within the IL-23/IL-17 axis. Specifically, there are several targets within the IL-23/IL-17 pathways for potential pharmacological intervention with antibodies or small molecule inhibitors. These targets...

  • Differential regulation of interleukin 17 and interferon γ production in inflammatory bowel disease. L Rovedatti // Gut;Dec2009, Vol. 58 Issue 12, p1629 

    BACKGROUND AND AIMS: Interleukin 17 (IL17) is now known to be involved in a number of chronic inflammatory disorders. However, the mechanisms regulating its production in inflammatory bowel disease (IBD) are still unclear. METHODS: Endoscopic biopsies or surgical specimens were taken from...

  • Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients Brown, Kurt A.; Back, Susan J.; Ruchelli, Eduardo D.; Markowitz, Jonathan; Mascarenhas, Maria; Verma, Ritu; Piccoli, David A.; Baldassano, Robert N. // American Journal of Gastroenterology;Oct2002, Vol. 97 Issue 10, p2603 

    OBJECTIVES:Understanding cytokine production patterns in early mucosal lesions of pediatric patients newly diagnosed with inflammatory bowel disease (IBD) may be critical to understanding IBD pathogenesis. Interleukin-6 (IL-6) has a central role in a multitude of immune system reactions;...

  • Role of Interleukin-21 in Inflammation and Allergy. Fina, Daniele; Fantini, Massimo Claudio; Pallone, Francesco; Monteleone, Giovanni // Inflammation & Allergy - Drug Targets;Jan2007, Vol. 6 Issue 1, p63 

    Interleukin-21 (IL-21) is a newly described cytokine, produced by activated CD4+ T cells. Since the discovery in 2000, IL-21 has been the object of intensive research because of its homology to IL-2, IL-4 and IL-15, and its ability to modulate both innate and adaptive immune responses. IL-21...

  • The IL-33/ST2 axis: yet another therapeutic target in inflammatory bowel disease? Salas, Azucena // Gut;Oct2013, Vol. 62 Issue 10, p1392 

    The author reflects on interleukin-33 (IL-33), a cytokine, produced in human inflammatory bowel disease (IBD) whose gene can be used as a therapeutic target. She mentions that IL-33 induces increase in levels of immunoglobulin IgE and IgA, induces production of mediators such as tumor necrosis...

  • Oral Administration of Interleukin-10 and Anti-IL-1 Antibody Ameliorates Experimental Intestinal Inflammation. Cardani, Diego; Dusio, Giuseppina F.; Luchini, Patrizia; Sciarabba, Michele; Solimene, Umberto; Rumio, Cristiano // Gastroenterology Research;Aug2013, Vol. 6 Issue 4, p124 

    Background: To elucidate the effects of a solution containing interleukin-10 and anti-IL-1 antibody in modulating experimental intestinal inflammation. Methods: Colitis was induced in BALB/c mice by oral administration of dextran sodium sulphate; mice were then treated with interleukin-10 plus...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics